Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 28 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Acute myeloid leukemiaThis series is part of our curated briefing on it.
- Samples
- 28 samples: 10 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionLeukemia · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE247095_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1036204 and SRA study SRP470431. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 20 samples.
How we read this: 10 replicated groups read from 28 sample titles; they account for 20 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7883110 AML191 Control 1 AML191 Control
- GSM7883111 AML191 Control 2 AML191 Control
- GSM7883112 AML191 200 nM BC2059 1 AML191 200 nM BC2059
- GSM7883113 AML191 200 nM BC2059 2 AML191 200 nM BC2059
- GSM7883114 UCSD-AML1 Control 1 UCSD-AML1 Control
- GSM7883115 UCSD-AML1 Control 2 UCSD-AML1 Control
- GSM7883116 UCSD-AML1 100 nM BC2059 1 UCSD-AML1 100 nM BC2059
- GSM7883117 UCSD-AML1 100 nM BC2059 2 UCSD-AML1 100 nM BC2059
- GSM7883118 OCI-AML20 Control 1 OCI-AML20 Control
- GSM7883119 OCI-AML20 Control 2 OCI-AML20 Control
- GSM7883120 OCI-AML20 100 nM BC2059 1 OCI-AML20 100 nM BC2059
- GSM7883121 OCI-AML20 100 nM BC2059 2 OCI-AML20 100 nM BC2059
- GSM7883122 AML191_control_1 AML191_control
- GSM7883123 AML191_control_2 AML191_control
- GSM7883124 AML191_100BC_1 AML191_100BC
- GSM7883125 AML191_100BC_2 AML191_100BC
- GSM7883126 AML191_Control_H3K27Ac
- GSM7883127 AML191_BC2059_H3K27Ac
- GSM7883128 AML191_Ctrl_H3K27Ac_Hi_ChIP 1 AML191_Ctrl_H3K27Ac_Hi_…
- GSM7883129 AML191_Ctrl_H3K27Ac_Hi_ChIP 2 AML191_Ctrl_H3K27Ac_Hi_…
- GSM7883130 AML191_BC2059_H3K27Ac_Hi-ChIP 1 AML191_BC2059_H3K27Ac_H…
- GSM7883131 AML191_BC2059_H3K27Ac_Hi-ChIP 2 AML191_BC2059_H3K27Ac_H…
- GSM7883132 AML191_Control_input
- GSM7883133 AML191_BC2059_input
- GSM7883134 AML191_H3K4me1_BC
- GSM7883135 AML191_H3K4me1_Ctrl
- GSM7883136 AML191_H3K4me1_input_BC
- GSM7883137 AML191_H3K4me1_input_Ctrl
- GSE122515 Bonn Dataset 3 of meta-analysis on AML classification, RNAseq dataset 0 samples same disease briefing · shares aml
- GSE129437 Genome-wde mapping of BRD9 binding sites and gene expression changes upon BRD9 knockdown 6 samples same disease briefing
- GSE137851 The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia 387 samples same disease briefing
- GSE270185 Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia 249 samples same disease briefing
- GSE137574 Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells 24 samples same disease briefing
- GSE303795 Halofuginone exerts broad-spectrum cytotoxic effects by regulating p-eIF2α-S100A8/A9-calcium signaling, inhibiting global protein synthesis, and reversing the resistance of idarubicin in acute myeloid leukemia 6 samples same disease briefing
- GSE252938 BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 34 samples shares aml, preclinical, efficacy
- GSE289713 Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations 11 samples shares aml, preclinical, efficacy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.